Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$370.10 USD

370.10
202,872

+1.08 (0.29%)

Updated Nov 7, 2024 12:23 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sheraz Mian headshot

Top Stock Reports for Toyota Motor, IBM & Stryker

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corporation (TM), International Business Machines Corporation (IBM) and Stryker Corporation (SYK), as well a micro-cap stock Fossil Group, Inc. (FOSL).

Reasons to Retain Stryker Stock in Your Portfolio for Now

by Zacks Equity Research

SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

by Zacks Equity Research

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio

by Zacks Equity Research

Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.

Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare

by Zacks Equity Research

Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.

Stryker's (SYK) Pangea System to Enhance Plating Solutions

by Zacks Equity Research

Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Are Medical Stocks Lagging Stryker (SYK) This Year?

by Zacks Equity Research

Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.

Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 0.72% and 0.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Can These 3 Medical Device Stocks Hit Earnings This Season?

by Zacks Equity Research

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

by Zacks Equity Research

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

by Zacks Equity Research

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

by Zacks Equity Research

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

by Zacks Equity Research

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment

by Zacks Equity Research

GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.